Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy
View todays social media effects on GILD
View the latest stocks trending across Twitter. Click to view dashboard
See who Gilead is hiring next, click here to view
